Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 327-334 , June 2007

The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes

Received 21 November 2005 ,Accepted 4 September 2006.

References 

  1. De Fronzo RA, Bonadonna RC, Ferraninni E. Pathogenesis of NIDDM—a balanced overview. Diabetes Care. 1992;15:318–368
  2. Rossetti L, Giaccari A, De Fronzo RA. Glucose toxicity. Diabetes Care. 1990;13:610–630
  3. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia. 1985;28:119–121
  4. Robertson RP, Zhang HJ, Pyzdrowski KL, Walseth TF. Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. J. Clin. Invest. 1992;90:320–325
  5. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, et al. Reduction of postprandial hyperglycaemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46:265–270
  6. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904–1909
  7. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with Type 1 diabetes. Diabetes Care. 2000;23:583–588
  8. Lindholm A, McEwen J, Riis AP. Improved postprandial glycaemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801–805
  9. Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Med. 2000;17:762–770
  10. Anderson JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin. Ther. 1997;19:62–72
  11. Anderson JH, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L. Mealtime treatment with insulin analog improves postprandial hyperglycaemia and hypoglycaemia in patients with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 1997;157:1249–1255
  12. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycaemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539–1542
  13. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41–46
  14. Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, et al. Insulin secretory abnormalities in subjects with hyperglycaemia due to glucokinase mutations. J. Clin. Invest. 1994;93:1120–1130
  15. Butler TJ, Barriocanal LA, Walker M. Elevated plasma non-esterified fatty acid levels and insulin secretion in non-diabetic relatives of type 2 diabetic patients. Clin. Endocrinol. 2001;55:349–355
  16. Gallagher A, Home PD. The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes. Diabetes Res. Clin. Practice. 2005;67:196–203
  17. Christensen C, Orskov C. Rapid screening PEG radioimmunoassay for quantification of pathological microalbuminuria. Diabetic Nephropathy. 1984;3:92–97
  18. Polonsky K, Frank B, Pugh W, Addis A, Karrison T, Meier P, et al. The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes. 1986;35:379–386
  19. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes. 1992;41:368–377
  20. Mosteller RD. Simplified calculation of body-surface area. N. Engl. J. Med. 1987;317:1098
  21. Home PD, Barriocanal L, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. 1999;55:199–203
  22. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy non-diabetic subjects. Diabetes Care. 1999;22:1501–1506
  23. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycaemia in patients with type 2 diabetes. JAMA. 2006;295:1681–1687
  24. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycaemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J. Am. Coll. Cardiol. 1999;34:146–154
  25. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabetic Med. 2004;21:171–175
  26. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR for the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–336
  27. Turner RC, Cull CA, Frighi V, Holman RR. Glycaemic control with diet, sulfonylureas, metformin or insulin in patients with type 2 diabetes. JAMA. 1999;281:2005–2012

PII: S0168-8227(06)00385-8

doi: 10.1016/j.diabres.2006.09.001

Diabetes Research and Clinical Practice
Volume 76, Issue 3 , Pages 327-334 , June 2007

Article Tools

* Image Usage & Resolution